Clinical Trials
3 trialsNCT02051218 2025-12-30
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
Swiss Cancer Institute
Phase 3 Active not recruiting
NCT04711109 2025-04-02
BRCA-P
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT03324932 2023-10-06
Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer
Kyoto Prefectural University of Medicine
Phase 3 Active not recruiting